Summaries
NHS hepatitis C antibody testing guidance for community pharmacy
Summarised information on offering HCV antibody testing in community pharmacy
COVID-19 rapid guideline on gastrointestinal and liver conditions affecting immune response
A summary of guidance intended to maximise the safety of children and adults with gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic
Early identification and referral of liver disease in infants
This Guidelines summary is based on guidance included within the Children’s Liver Disease Foundation Yellow Alert Pack, written to provide general guidelines on the early identification of liver disease in infants and their referral where appropriate.
CLDF guideline: Yellow Alert stool chart
A summary of the CLDF's Yellow Alert stool chart—for tracking the colour of newborn babies' stools and being alert to warning signs of prolonged jaundice.
BSG liver blood tests guideline
This summary covers the key points for GPs to consider when interpreting results from liver blood tests and how to respond to detected abnormalities.
Educational resources
Management of hepatic encephalopathy in primary care
This management algorithm has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
View TARGAXAN® (rifaximin-α) prescribing and adverse event reporting information
UK-HEP-XIF-2100040 October 2021
Test and reflect
MHRA highlights liver injury risk with combination therapy for cystic fibrosis
Record-breaking rise in alcohol-related deaths during COVID
Management of hepatic encephalopathy in primary care
BSG joint statement: COVID-19 booster vaccination and liver disease
NHS hepatitis C antibody testing guidance for community pharmacy